Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Current Leases (2021 - 2025)

Historic Current Leases for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $75.0 million.

  • Rxo's Current Leases fell 740.74% to $75.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $75.0 million, marking a year-over-year decrease of 740.74%. This contributed to the annual value of $75.0 million for FY2025, which is 740.74% down from last year.
  • Latest data reveals that Rxo reported Current Leases of $75.0 million as of Q4 2025, which was down 740.74% from $77.0 million recorded in Q3 2025.
  • Rxo's Current Leases' 5-year high stood at $81.0 million during Q4 2024, with a 5-year trough of $42.0 million in Q4 2021.
  • For the 5-year period, Rxo's Current Leases averaged around $60.3 million, with its median value being $54.0 million (2024).
  • Its Current Leases has fluctuated over the past 5 years, first surged by 5283.02% in 2024, then tumbled by 740.74% in 2025.
  • Over the past 5 years, Rxo's Current Leases (Quarter) stood at $42.0 million in 2021, then grew by 14.29% to $48.0 million in 2022, then rose by 10.42% to $53.0 million in 2023, then skyrocketed by 52.83% to $81.0 million in 2024, then dropped by 7.41% to $75.0 million in 2025.
  • Its last three reported values are $75.0 million in Q4 2025, $77.0 million for Q3 2025, and $75.0 million during Q2 2025.